# Managing Refractory Diarrhea in Metastatic Breast Cancer
> A clinical review of diagnostic challenges for refractory diarrhea following chemotherapy and immunotherapy, focusing on C. diff, CMV, and IO-colitis.

Tags: oncology, pembrolizumab, clostridioides-difficile, immunotherapy-side-effects, clinical-case-study, medical-education
## Refractory Diarrhea in Metastatic Breast Cancer
* **Presentation:** Diagnostic dilemmas post-chemotherapy and immunotherapy (Pembrolizumab) for an oncology ward review.

## Patient Profile & Admission
* **Patient:** Middle-aged female with metastatic breast cancer.
* **History:** Day 10 post-chemotherapy cycle; currently on Pembrolizumab.
* **Symptoms:** Nausea, vomiting, abdominal pain, and non-bloody loose stools.

## Initial Clinical Assessment
* **Findings:** Fast Atrial Fibrillation (AF) and Tachycardia.
* **Biochemistry:** 
  * CRP > 400 mg/L (Severe Inflammation)
  * Hypokalemia (Low K+)
  * Hypomagnesemia (Low Mg+)
  * AKI Stage 2

## Management & Response
* **Interventions:** IV fluids, electrolyte replacement, and empiric IV Ceftazidime.
* **Outcome:** AKI and AF resolved; CRP improved, but diarrhea persisted with high frequency.

## Diagnostic Dilemma: Stool Analysis
* **Results:** PCR Positive (+), Toxin Negative (-).
* **Decision:** Due to immunocompromised status and active colitis symptoms, treated as active C. diff infection despite negative toxin.

## Refractory Course & Escalation
* **Therapy:** Oral Vancomycin escalated to Fidaxomicin + IV Metronidazole.
* **Failure:** Stool frequency increased to 18-22 episodes per day.

## Endoscopic Investigation
* **Visual Finding:** Pseudomembranous Colitis (yellow-white plaques) via flexible sigmoidoscopy.
* **Suspicion:** Potential co-pathology given failure of maximal C. diff therapy.

## Differentials for Refractory Diarrhea
* **Pembrolizumab-Induced Colitis:** Immune checkpoint inhibitor (PD-1) causing autoimmune damage (2-5% prevalence).
* **CMV Colitis:** IgM weakly positive; pending PCR viral load and IHC biopsy.

## Current Strategy
* **Pharmacological:** Switched to high-dose oral Vancomycin (250mg every 4 hours).
* **Advanced:** Proposed Fecal Microbiota Transplant (FMT) awaiting microbiology review.

## Summary
* Refractory diarrhea in oncology is often multifactorial (infection vs. toxicity).
* Aggressive treatment is validated in immunocompromised hosts even with mixed stool results.
* Always consider IO-colitis and CMV reactivation in treatment-resistant cases.
---
This presentation was created with [Bobr AI](https://bobr.ai) — an AI presentation generator.